{"preliminary_commentary":{"by_channel":{"bluesky_thread":134,"podcast":21,"youtube":17,"x_thread":15},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02374242\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ABC","nct_id":"NCT02374242","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=abc-nct02374242. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ABC","arms":[{"description":"Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.\n\nAfter 52 weeks, nivolumab dosing can change to 480mg every 4 weeks","label":"Cohort 1 Nivolumab Monotherapy","type":"ACTIVE_COMPARATOR"},{"description":"Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.\n\nAfter 52 weeks, nivolumab dosing can change to 480mg every 4 weeks","label":"Cohort 2 Nivolumab Monotherapy","type":"ACTIVE_COMPARATOR"},{"description":"Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.\n\nAfter 52 weeks, nivolumab dosing can change to 480mg every 4 weeks","label":"Cohort 3 Nivolumab and Ipilimumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Melanoma and Skin Cancer Trials Limited","Bristol-Myers Squibb"],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Melanoma","Brain Metastases"],"enrollment":{"count":76,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo","BMS-936558"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"],"type":"DRUG"}],"last_update":"2025-12-10","lead_sponsor":"Melanoma Institute Australia","official_title":"A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2017-09-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Intracranial response rate","timeFrame":"Approximately 3 years"}],"references":[{"citation":"Long GV, Atkinson V, Lo SN, Guminski AD, Sandhu SK, Brown MP, Gonzalez M, McArthur GA, Menzies AM. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2025 Mar;26(3):320-330. doi: 10.1016/S1470-2045(24)00735-6. Epub 2025 Feb 17.","pmid":"39978375","type":"DERIVED"},{"citation":"Thompson JR, Lai-Kwon J, Morton RL, Guminski AD, Gonzalez M, Atkinson V, Sandhu S, Brown MP, Menzies AM, McArthur GA, Lo SN, Long GV, Bartula I. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy. 2023 Jun;15(8):593-610. doi: 10.2217/imt-2022-0262. Epub 2023 May 2.","pmid":"37132182","type":"DERIVED"},{"citation":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.","pmid":"29602646","type":"DERIVED"}],"start_date":{"date":"2014-11-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","url":"https://clinicaltrials.gov/study/NCT02374242"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/abc-nct02374242"}